查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1574933

皰疹樣皮膚炎市場，按藥物類別、給藥途徑、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Dermatitis Herpetiformis Market, By Drug Class, By Route of Administration, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年皰疹樣皮膚炎市場規模為3.0103億美元，2024年至2032年複合年成長率為7.29%。

治療通常涉及嚴格的無麩質飲食，這有助於減輕症狀並預防未來的爆發。藥物也可用於緩解搔癢和發炎。早期診斷和適當的管理對於改善受影響者的生活品質非常重要。

皰疹樣皮膚炎市場-市場動態

人們對麩質敏感性及其皮膚表現的認知不斷提高，推動了需求。

人們日益認知到麩質敏感性及其與皰疹樣皮膚炎 (DH) 等皮膚病的聯繫，這是市場的關鍵驅動力。越來越多的人認知到麩質不耐症的症狀，這增加了對 DH 檢測和治療的需求。美國國立衛生研究院 (NIH) 指出，美國每 141 人中約有 1 人患有乳糜瀉，與 DH 密切相關。這種不斷提高的意識鼓勵醫療保健提供者和患者尋求更好的檢測和管理選擇。因此，製藥公司和健康組織正在專注於開發具體的治療方法和教育材料，以幫助解決這個問題，促進市場成長。

皰疹樣皮膚炎市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 7.29% 左右的複合年成長率成長

根據藥物類別細分，預計氨苯碸將在 2023 年顯示出最大的市場佔有率

根據給藥途徑細分，2023年口服是領先類型

根據最終用戶，醫院是 2023 年的主導類型

按地區分類，北美是 2023 年的主要收入來源

皰疹樣皮膚炎市場-細分分析：

全球皰疹樣皮膚炎市場根據藥物類別、給藥途徑、最終用戶和地區進行細分。

根據藥物類別，市場分為三類：氨苯碸、外用皮質類固醇和抗組織胺。氨苯碸是最重要的。氨苯碸是一種抗生素，有助於減少與此疾病相關的搔癢和發炎。它能有效清除皮膚病變，使其成為許多醫師的首選。其快速作用和緩解症狀的能力使其在治療選擇中脫穎而出。氨苯碸的有效性導致其廣泛使用和推薦，從而推動其在皰疹樣皮膚炎市場中的突出地位。

根據給藥途徑，市場分為兩類：口服、外用和注射。口服給藥途徑是最重要且最突出的。這是因為口服藥物（如氨苯碸和其他治療方法）服用方便並且可以有效緩解症狀。患者更喜歡口服治療，因為它們方便且非侵入性，並且可以更輕鬆地隨著時間的推移控制病情。注射劑和局部用藥可供選擇，但由於不適或需要更頻繁的使用等因素，它們不太受歡迎。總體而言，口服藥物在有效治療皰疹樣皮膚炎方面發揮關鍵作用。

皰疹樣皮膚炎市場-地理洞察

北美皰疹樣皮膚炎市場非常重要，因為自體免疫疾病的數量很高，而且人們對皮膚狀況的認知也越來越高。美國憑藉其先進的醫療保健系統和強大的研究力量在這個市場上處於領先地位。

在許多臨床試驗和批准的支持下，更多的創新療法和療法正在變得可用。加拿大也透過注重病患教育和支持，在市場成長中發揮作用。該地區有許多大型製藥公司，有許多合作和創新。

皰疹樣皮膚炎市場-競爭格局：

皰疹樣皮膚炎市場競爭激烈，有幾個主要參與者參與其中。葛蘭素史克、艾伯維和諾華等大公司開發自體免疫性皮膚病的治療方法。他們投資研究以改進現有療法並創造新療法。輝瑞（Pfizer）和強生（Johnson & Johnson）等公司也向市場提供創新產品。

此外，像 Aclaris Therapeutics 這樣的小公司透過專注於利基治療而實現了成長。總體而言，在協作和創新的推動下，加強皰疹樣皮膚炎管理的前景是動態的。

最新進展：

2023 年 5 月，艾伯維 (AbbVie) 美容部門擴大了其產品陣容，最近 FDA 批准了一款名為 Skinvive 的新產品。本週獲得的批准增加了 Allergan 的 Juvederm 真皮填充劑系列。

目錄

第 1 章：皰疹樣皮膚炎市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類別分類的皰疹樣皮膚炎市場片段
    • 依給藥途徑分類的皰疹樣皮膚炎市場片段
    • 最終用戶的皰疹樣皮膚炎市場片段
    • 按國家/地區分類的皰疹樣皮膚炎市場片段
    • 按地區分類的皰疹樣皮膚炎市場片段
  • 競爭洞察

第 3 章：皰疹樣皮膚炎主要市場趨勢

  • 皰疹樣皮膚炎市場促進因素
    • 市場促進因素的影響分析
  • 皰疹樣皮膚炎市場限制
    • 市場限制影響分析
  • 皰疹樣皮膚炎市場機會
  • 皰疹樣皮膚炎市場未來趨勢

第 4 章：皰疹樣皮膚炎產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：皰疹樣皮膚炎市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：皰疹樣皮膚炎市場格局

  • 皰疹樣皮膚炎市場佔有率分析，2023 年
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：皰疹樣皮膚炎市場 - 依藥物類別

  • 概述
    • 按藥品類別分類的細分市場佔有率分析
  • 氨苯碸
  • 外用皮質類固醇
  • 抗組織胺藥

第 8 章：皰疹樣皮膚炎市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市場佔有率分析
    • 口服
    • 專題
    • 可注射

第 9 章：皰疹樣皮膚炎市場 - 按最終用戶

  • 概述
    • 按最終用戶分類的細分市場佔有率分析
    • 醫院
    • 皮膚科診所
    • 家庭護理設置
    • 其他

第 10 章：皰疹樣皮膚炎市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 皰疹樣皮膚炎北美主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲皰疹樣皮膚炎主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥品類別）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 皰疹樣皮膚炎亞太地區主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲皰疹樣皮膚炎主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模和預測（按藥品類別）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲皰疹樣皮膚炎主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（依藥品類別）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 11 章：主要供應商分析 - 皰疹樣皮膚炎產業

  • 競爭儀表板
  • 公司簡介
    • GlaxoSmithKline
    • AbbVie
    • Amgen
    • Celgene (Bristol-Myers Squibb)
    • Novartis
    • Pfizer
    • Johnson & Johnson
    • Mylan
    • Takeda Pharmaceuticals
    • AstraZeneca
    • Regeneron Pharmaceuticals
    • Sanofi
    • Eli Lilly and Company
    • Dermira
    • Aclaris Therapeutics
    • Incyte Corporation
    • Teva Pharmaceutical Industries

第 12 章：360 度分析師視角

第 13 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3932

REPORT HIGHLIGHT

Dermatitis Herpetiformis Market size was valued at USD 301.03 Million in 2023, expanding at a CAGR of 7.29% from 2024 to 2032.

Dermatitis herpetiformis is a skin condition that causes itchy, blistering rashes. Dermatitis herpetiformis is linked to celiac disease, so it often occurs in people who cannot eat gluten, a protein found in wheat. When someone with celiac disease eats gluten, their body reacts by causing this skin rash. The rash usually appears on the elbows, knees, and buttocks but can show up anywhere on the body.

Treatment typically involves a strict gluten-free diet, which helps reduce symptoms and prevent future outbreaks. Medications can also be used to relieve itching and inflammation. Early diagnosis and proper management are important to improve the quality of life for those affected.

Dermatitis Herpetiformis Market- Market Dynamics

Growing awareness of gluten sensitivity and its skin manifestations drives demand.

The growing awareness of gluten sensitivity and its link to skin conditions like dermatitis herpetiformis (DH) is a key driver for the market. More people are recognizing the symptoms of gluten intolerance, which is increasing the demand for tests and treatments for DH. The National Institutes of Health (NIH) states that about 1 in 141 people in the U.S. has celiac disease, closely related to DH. This rising awareness encourages both healthcare providers and patients to seek better testing and management options. As a result, pharmaceutical companies and health organizations are focusing on developing specific treatments and educational materials to help address this condition, boosting market growth.

Dermatitis Herpetiformis Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.29% over the forecast period (2024-2032)

Based on Drug Class segmentation, Dapsone was predicted to show maximum market share in the year 2023

Based on Route of Administration segmentation, Oral was the leading type in 2023

Based on End Users, Hospitals was the leading type in 2023

based on Region, North America was the leading revenue generator in 2023

Dermatitis Herpetiformis Market- Segmentation Analysis:

The Global Dermatitis Herpetiformis Market is segmented based on Drug Class, Route of Administration, End User, and Region.

The market is divided into three categories based on Drug Class: Dapsone, Topical corticosteroids, and Antihistamines. Dapsone is the most significant. Dapsone is an antibiotic that helps reduce itching and inflammation associated with the condition. It works effectively to clear up skin lesions, making it a preferred choice for many doctors. Its quick action and ability to provide relief from symptoms make it stand out in the treatment options. Dapsone's effectiveness leads to its wide use and recommendation, driving its prominence in the dermatitis herpetiformis market.

The market is divided into two categories based on the Route of Administration: Oral, Topical, and Injectable. The oral route of administration is the most significant and prominent. This is because oral medications, like dapsone and other treatments, are convenient to take and offer effective relief from symptoms. Patients prefer oral treatments since they are convenient and non-invasive, making it simpler to manage the condition over time. Injectable and topical options are available, but they are less favored due to factors like discomfort or the need for more frequent applications. Overall, oral medications play a key role in managing dermatitis herpetiformis effectively.

Dermatitis Herpetiformis Market- Geographical Insights

The North American Dermatitis Herpetiformis market is important because of the high number of autoimmune diseases and greater awareness of skin conditions. The United States leads this market, thanks to its advanced healthcare system and strong research efforts.

More innovative treatments and therapies are becoming available, backed by many clinical trials and approvals. Canada also plays a role in market growth by focusing on patient education and support. With many major pharmaceutical companies in the region, there's a lot of collaboration and innovation.

Dermatitis Herpetiformis Market- Competitive Landscape:

The Dermatitis Herpetiformis market is competitive, with several key players involved. Major companies like GlaxoSmithKline, AbbVie, and Novartis develop treatments for autoimmune skin diseases. They invest in research to improve existing therapies and create new ones. Firms like Pfizer and Johnson & Johnson also contribute innovative products to the market.

Furthermore, smaller companies like Aclaris Therapeutics are seeing growth by specializing in niche treatments. Overall, the landscape is dynamic, driven by collaboration and innovation to enhance the management of Dermatitis herpetiformis.

Recent Developments:

In May 2023, AbbVie's aesthetics division expanded its product lineup with a recent FDA approval for a new product called Skinvive. This approval, granted this week, added to Allergan's Juvederm dermal filler range.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL DERMATITIS HERPETIFORMIS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • GlaxoSmithKline
  • AbbVie
  • Amgen
  • Celgene (Bristol-Myers Squibb)
  • Novartis
  • Pfizer
  • Johnson & Johnson
  • Mylan
  • Takeda Pharmaceuticals
  • AstraZeneca
  • Regeneron Pharmaceuticals
  • Sanofi
  • Eli Lilly and Company
  • Dermira
  • Aclaris Therapeutics
  • Incyte Corporation
  • Teva Pharmaceutical Industries

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Dapsone
  • Topical corticosteroids
  • Antihistamines

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Topical
  • Injectable

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Dermatology Clinics
  • Homecare Settings
  • Others

GLOBAL DERMATITIS HERPETIFORMIS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Dermatitis Herpetiformis Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Dermatitis Herpetiformis Market Snippet by Drugs Class
    • 2.1.2. Dermatitis Herpetiformis Market Snippet by Route of Administration
    • 2.1.3. Dermatitis Herpetiformis Market Snippet by End User
    • 2.1.4. Dermatitis Herpetiformis Market Snippet by Country
    • 2.1.5. Dermatitis Herpetiformis Market Snippet by Region
  • 2.2. Competitive Insights

3. Dermatitis Herpetiformis Key Market Trends

  • 3.1. Dermatitis Herpetiformis Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Dermatitis Herpetiformis Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Dermatitis Herpetiformis Market Opportunities
  • 3.4. Dermatitis Herpetiformis Market Future Trends

4. Dermatitis Herpetiformis Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Dermatitis Herpetiformis Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Dermatitis Herpetiformis Market Landscape

  • 6.1. Dermatitis Herpetiformis Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Dermatitis Herpetiformis Market - By Drugs Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drugs Class, 2023 & 2032 (%)
  • 7.2. Dapsone
  • 7.3. Topical corticosteroids
  • 7.4. Antihistamines

8. Dermatitis Herpetiformis Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Topical
    • 8.1.4. Injectable

9. Dermatitis Herpetiformis Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Dermatology Clinics
    • 9.1.4. Homecare Settings
    • 9.1.5. Others

10. Dermatitis Herpetiformis Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Dermatitis Herpetiformis Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Dermatitis Herpetiformis Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Dermatitis Herpetiformis Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Dermatitis Herpetiformis Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Dermatitis Herpetiformis Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drugs Class, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Dermatitis Herpetiformis Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. GlaxoSmithKline
    • 11.2.2. AbbVie
    • 11.2.3. Amgen
    • 11.2.4. Celgene (Bristol-Myers Squibb)
    • 11.2.5. Novartis
    • 11.2.6. Pfizer
    • 11.2.7. Johnson & Johnson
    • 11.2.8. Mylan
    • 11.2.9. Takeda Pharmaceuticals
    • 11.2.10. AstraZeneca
    • 11.2.11. Regeneron Pharmaceuticals
    • 11.2.12. Sanofi
    • 11.2.13. Eli Lilly and Company
    • 11.2.14. Dermira
    • 11.2.15. Aclaris Therapeutics
    • 11.2.16. Incyte Corporation
    • 11.2.17. Teva Pharmaceutical Industries

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us